Text Revisions to the Invited Commentary on Selective vs Routine Cholangiography Across a Health Care Enterprise
-
November 1, 2026
November 1, 2026
The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .
by Mouj Hijazi
October 27, 2026
Board-certified neurosurgeon Jonathan Miller, M.D., has joined Marcus Neuroscience Institute, a part of Baptist Health.
Cholangiocarcinoma, or bile duct cancer, is one of the most difficult cancers to diagnose and treat.